Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

被引：111

作者：

Empey, Kerry M. ^{[1
]}

Peebles, R. Stokes, Jr. ^{[3
]}

Kolls, Jay K. ^{[2
,4
]}

机构：

[1] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA

[2] Univ Pittsburgh, Dept Pediat, Div Pediat Pulmonol Allergy & Immunol, Pittsburgh, PA 15261 USA

[3] Vanderbilt Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Nashville, TN 37212 USA

[4] LSU, Hlth Sci Ctr, Sch Med, Dept Genet, New Orleans, LA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2010年 / 50卷 / 09期

基金：

美国国家卫生研究院;

关键词：

AFRICAN-GREEN MONKEYS; TRANSCRIPTION ELONGATION-FACTOR; G-GLYCOPROTEIN; MONOCLONAL-ANTIBODY; ANTIVIRAL ACTIVITY; VACCINE CANDIDATE; RNA INTERFERENCE; ENHANCED DISEASE; RSV INFECTION; BALB/C MICE;

D O I：

10.1086/651603

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable. During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens. This article reviews these obstacles and presents the novel development strategies used to overcome many of them. Also discussed are promising new antiviral treatment candidates and their associated mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacologic manipulation of the host response to RSV disease.

引用

页码：1258 / 1267

页数：10

共 121 条

[1] Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children [J].

Abarca, Katia ;

Jung, Elizabeth ;

Fernandez, Pilar ;

Zhao, Liang ;

Harris, Brian ;

Connor, Edward M. ;

Losonsky, Genevieve A. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) :267-272

[2] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections [J].

Abramson, JS ;

Baker, CJ ;

Baltimore, RS ;

Bocchini, JA ;

Long, SS ;

McMillan, JA ;

Meissner, HC ;

Powell, KR ;

Prober, CG ;

Rennels, MB ;

Saari, TN ;

Weiner, LB ;

Blackmon, L ;

Batton, DG ;

Bell, EF ;

Denson, SE ;

Engle, WA ;

Kanto, WP ;

Martin, GI ;

Stark, AR .

PEDIATRICS, 2003, 112 (06) :1447-1452

[3]

*ALN PHARM, ALN RSV01 RESP SYNC

[4] RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy [J].

Alvarez, Rene ;

Elbashir, Sayda ;

Borland, Todd ;

Toudjarska, Ivanka ;

Hadwiger, Philipp ;

John, Mathias ;

Roehl, Ingo ;

Morskaya, Svetlana Shulga ;

Martinello, Rick ;

Kahn, Jeffrey ;

Van Ranst, Mark ;

Tripp, Ralph A. ;

DeVincenzo, John P. ;

Pandey, Rajendra ;

Maier, Martin ;

Nechev, Lubomir ;

Manoharan, Muthiah ;

Kotelianski, Victor ;

Meyers, Rachel .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3952-3962

[5] Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus [J].

Andries, K ;

Moeremans, M ;

Gevers, T ;

Willebrords, R ;

Sommen, C ;

Lacrampe, J ;

Janssens, F ;

Wyde, PR .

ANTIVIRAL RESEARCH, 2003, 60 (03) :209-219

[6] Inhibition of respiratory viruses by nasally administered siRNA [J].

Bitko, V ;

Musiyenko, A ;

Shulyayeva, O ;

Barik, S .

NATURE MEDICINE, 2005, 11 (01) :50-55

[7] Discovery of a new class of polycyclic RSV inhibitors [J].

Bond, Silas ;

Draffan, Alistair ;

Lambert, John ;

Lim, Chin-Yu ;

Lin, Bo ;

Luttick, Angela ;

Mitchell, Jeff ;

Morton, Craig ;

Nearn, Roland ;

Sanford, Vanessa ;

Tucker, Simon .

ANTIVIRAL RESEARCH, 2007, 74 (03) :A30-A30

[8] Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121) [J].

Bonfanti, Jean-Francois ;

Meyer, Christophe ;

Doublet, Frederic ;

Fortin, Jerome ;

Muller, Philippe ;

Queguiner, Laurence ;

Gevers, Tom ;

Janssens, Peggy ;

Szel, Heidi ;

Willebrords, Rudy ;

Timmerman, Philip ;

Wuyts, Koen ;

van Remoortere, Pieter ;

Janssens, Frans ;

Wigerinck, Piet ;

Andries, Koen .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) :875-896

[9]

BONFANTI JF, 2009, OPIN DRUG DISCOV DEV, V12, P479

[10] RNA interference: genetic wand and genetic watchdog [J].

Bosher, JM ;

Labouesse, M .

NATURE CELL BIOLOGY, 2000, 2 (02) :E31-E36

← 1 2 3 4 5 6 7 8 9 10 →